CTOs on the Move

Health Decisions

www.HealthDec.com

 
Health Decisions (www.HealthDec.com) is a global clinical research organization (CRO) committed to helping drug and device companies achieve greater success. Our sponsors rely on us to help them prove the value of their pipelines both faster and with the smartest possible allocation of funds. Through Agile Clinical Development- a strategic combination of adaptive design and adaptive operations Health Decisions optimizes every facet of clinical research from design protocol to the most detailed day-to-day management, so sponsors can make the most of competitive market opportunities.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.HealthDec.com
  • 6350 Quadrangle Dr Ste 300
    Chapel Hill, NC USA 27517
  • Phone: 919.967.1111

Executives

Name Title Contact Details

Similar Companies

Pharmaka

Pharmaka is a Flemington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pivot Health

Pivot Health is a Brentwood, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cypress County - Family and Community Support Services

Cypress County - Family and Community Support Services is a Fort Mcmurray, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nebraska Methodist Health System

Methodist Health System, 3 hospitals, 21 clinic locations, a nursing and allied health college, in Omaha, NE

Ovid Therapeutics

Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing impactful medicines for patients and families living with rare neurological disorders. Ovid`s drug candidate, OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies. Ovid has initiated the Phase 2 STARS trial of OV101 in adults with Angelman syndrome and a Phase 1 trial in adolescents with Angelman and Fragile X syndrome to identify doses suitable for younger patients.